Back to top

immuno-therapy: Archive

Zacks Equity Research

Lilly (LLY) Hits Record High on Crohn's Disease Study Data

Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.

JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

AZNNegative Net Change BMYPositive Net Change MRKPositive Net Change LGNDNegative Net Change